Valneva Competitors and Similar CompaniesClear all
Valneva's competitors and similar companies include Novimmune, Theravectys, Virometix and Emergent Biosolutions.
 Valneva Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. |  Novimmune Novimmune is a company that focuses on its bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience. |  Virometix Virometix is a biotechnology company that develops vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases. |  Emergent Biosolutions Emergent Biosolutions is a biopharmaceutical company that provides vaccines and therapeutics against public health threats. | ||
Founding Date | Founding Date 2013 | Founding Date 1998 | Founding Date 2005 | Founding Date 2009 | Founding Date 1998 |
Type | Type Public | Type Private | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Plan-les-Ouates, CH HQ | Locations Paris, FR HQ Paris, FR | Locations Schlieren, CH HQ | Locations Gaithersburg, US HQ Mississauga, CA Winnipeg, CA Dublin, IE London, GB Canton, US Lansing, US see more | |
Employees | Employees 713 | Employees 80 | Employees 196% increase | Employees 18 | Employees 90044% decrease |
Valuation ($) | Valuation ($) 482.5 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 493.6 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €157.9m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $742.9m (FY, 2025) |
Cost of goods | Cost of goods €8.2m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $326.2m (FY, 2025) |
Gross profit | Gross profit €177.7m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $416.7m (FY, 2025) |
Net income | Net income (€115.2m) (FY, 2025) | Net income N/A | Net income N/A | Net income N/A | Net income $52.6m (FY, 2025) |
Funding | |||||
Latest funding round | Latest funding round N/A | Latest funding round $ 29.8m (over 10 years ago) | Latest funding round $ 2.1m (over 11 years ago) | Latest funding round $ 8m (almost 6 years ago) | Latest funding round N/A |
Total funding raised | Total funding raised $ 51.7m | Total funding raised $ 239.1m | Total funding raised $ 31.7m | Total funding raised $ 18.5m | Total funding raised $ 34.5m |
For sources of this data, please see the company profile
View Company Profiles
Novimmune
HQ
Plan-les-Ouates, CH
Employees
80
Novimmune is a company that focuses on its bispecific technology to build a pipeline of multispecific antibodies under the brand Light Chain Bioscience.
View companyVirometix
HQ
Schlieren, CH
Employees
18
Virometix is a biotechnology company that develops vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and chronic human diseases.
View companyEmergent Biosolutions
HQ
Gaithersburg, US
Employees
900↓ 44% decrease
Emergent Biosolutions is a biopharmaceutical company that provides vaccines and therapeutics against public health threats.
View company